Olema Pharmaceuticals, Inc. Logo

Olema Pharmaceuticals, Inc.

A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.

OLMA | US

Overview

Corporate Details

ISIN(s):
US68062P1066
LEI:
Country:
United States of America
Address:
780 BRANNAN STREET, 94103 SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Operating as Olema Oncology, the company is dedicated to transforming the standard of care, with a primary focus on breast cancer. Its lead product candidate, palazestrant (OP-1250), is a novel, investigational agent being developed for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Olema's mission is to develop more effective and tolerable medicines to improve patient outcomes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Olema Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Olema Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Olema Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
JW SHINYAK CORPORATION Logo
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea 067290
Jyong Biotech Ltd. Logo
Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.
United States of America MENS
Kadimastem Ltd. Logo
Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.
Israel KDST
kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan 4556
Kairos Pharma, LTD. Logo
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America KAPA
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan 4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel KMDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.